Loading company
Eupraxia Pharmaceuticals Inc.
EPRX · Nasdaq · ·
Next earnings: November 3, 2026
$8.30+1.0%Sep 29 close
- 1M
- +24.3%
- 6M
- +25.6%
- 1Y
- +40.7%
EPRX · Nasdaq · ·
Next earnings: November 3, 2026
$8.30+1.0%Sep 29 close
Eupraxia Pharmaceuticals Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
From the company’s own 6-K filing.
“The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE),”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
The quote and the company description come from the 6-K Eupraxia Pharmaceuticals Inc. filed on November 4, 2025 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Eupraxia Pharmaceuticals Inc. has no earnings call transcript available.